AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company ...
Bloomberg via Yahoo
1 day ago
